Weiping Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Weiping Liu has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Jun Zhu
Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital & Institute Beijing China
19 shared publications - Yuqin Song
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
16 shared publications Lan Mi
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China
9 shared publicationsMeng Wu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China
7 shared publicationsYuqin Song
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
7 shared publicationsChen Zhang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China
6 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy
- 14 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessLongitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy
- Open Access
- 7 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72153
Impact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma
The influence of bone marrow (BM) involvement at diagnosis on hematopoietic stem cell (HSC) mobilization outcomes remains to be fully elucidated, particularly in the contemporary plerixafor era. To address this issue, this multicenter retrospective cohort study including four lymphoma treatment centers evaluated patients who underwent their first autologous HSC mobilization procedure between January 2017 and June 2023. Mobilization success was defined as achieving a minimum CD34+ cell yield ≥ 2.0 × 10 6 cells/kg. Propensity score matching (PSM) was performed to rigorously adjust for baseline confounders and ensure robust group comparisons. The study cohort comprised 669 patients, of whom 138 (20.6%) presented with BM involvement at the time of diagnosis. Analyzes revealed that mobilization success rates were highly comparable between patients with and without BM involvement, both before (79.0% versus [vs.] 81.2%; p = 0.563) and after (79.1% vs. 83.5%; p = 0.500) PSM. Furthermore, the median CD34+ cell yield did not differ significantly between the 2 cohorts either before (3.2 vs. 3.7 × 10 6 /kg; p = 0.192) or after (3.2 vs. 3.5 × 10 6 /kg; p = 0.639) PSM. These findings indicate that initial BM involvement does not significantly impair the success of HSC mobilization in patients with lymphoma, a conclusion that remained highly consistent even after controlling for baseline variables.
- 7 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72153
Open AccessImpact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma
The influence of bone marrow (BM) involvement at diagnosis on hematopoietic stem cell (HSC) mobilization outcomes remains to be fully elucidated, particularly in the contemporary plerixafor era. To address this issue, this multicenter retrospective cohort study including four lymphoma treatment centers evaluated patients who underwent their first autologous HSC mobilization procedure between January 2017 and June 2023. Mobilization success was defined as achieving a minimum CD34+ cell yield ≥ 2.0 × 10 6 cells/kg. Propensity score matching (PSM) was performed to rigorously adjust for baseline confounders and ensure robust group comparisons. The study cohort comprised 669 patients, of whom 138 (20.6%) presented with BM involvement at the time of diagnosis. Analyzes revealed that mobilization success rates were highly comparable between patients with and without BM involvement, both before (79.0% versus [vs.] 81.2%; p = 0.563) and after (79.1% vs. 83.5%; p = 0.500) PSM. Furthermore, the median CD34+ cell yield did not differ significantly between the 2 cohorts either before (3.2 vs. 3.7 × 10 6 /kg; p = 0.192) or after (3.2 vs. 3.5 × 10 6 /kg; p = 0.639) PSM. These findings indicate that initial BM involvement does not significantly impair the success of HSC mobilization in patients with lymphoma, a conclusion that remained highly consistent even after controlling for baseline variables.
- Open Access
- 26 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (S3) , 79-84
Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single‐Arm Study
- 26 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (S3) , 79-84
Open AccessSafety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single‐Arm Study
- Open Access
- 14 March 2026
- Vol. 47 (3) , 241-246
[Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].
Objective: This study aimed to analyze the disease burden and trends of Burkitt lymphoma (BL) in China between 1990 and 2021. Methods: Based on the 2021 Global Burden of Disease Study data, stratified by age, sex, and region, the disease burden was analyzed by BL incidence, mortality, and disability-adjusted life year (DALY). Regression analysis was conducted with joinpoint software to calculate the average annual percentage change (AAPC) of age-standardized rates to analyze the changing trends and compare them with global data. Results: In 2021, a total of 1,322 new BL cases were reported in China, with an age-standardized incidence rate of 0.08/100,000. Of these patients, 241 died, with an age-standardized mortality rate of 0.01/100,000. DALY was 9,516 person-years, with an age-standardized DALY rate of 0.68/100,000. The disease burden of BL demonstrated significant differences across various age and sex groups. The highest BL disease burden was observed in the age group over 80 years old, with an incidence of 0.60/100,000, mortality of 0.11/100,000, and DALY rates of 1.59/100,000. BL disease burden was higher in males than in females, with age-standardized incidence rates of 0.11/100,000 and 0.05/100,000, age-standardized mortality rates of 0.02/100,000 and 0.01/100,000, and age-standardized DALY rates of 0.92/100,000 and 0.43/100,000, respectively. Significant regional differences were observed in BL disease burden. The highest-ranked age-standardized DALY rates were reported in Shanghai [1.78 (95% CI: 0.16-3.63) /100,000], Tibet Autonomous Region [1.15 (95% CI: 0.41-2.23) /100,000] and Qinghai Province[1.06 (95% CI: 0.49-1.87) /100,000], whereas the lowest-ranked were observed in Macao Special Administrative Region [0.32 (95% CI: 0.07-0.57) /100,000], Chongqing [0.36 (95% CI: 0.14-0.72) /100,000] and Ningxia Hui Autonomous Region [0.48 (95% CI: 0.25-0.92) /100,000]. From 1990 to 2021, the age-standardized incidence rate of BL increased by 187.12%, whereas the age-standardized mortality rate and age-standardized DALY rate decreased by 37.72% and 52.70%, respectively. The AAPCs were 3.49%, -1.46%, and -2.40%, respectively. Conclusions: The disease burden of BL in China has been alleviated to a certain extent; however, significant differences were observed among different ages, genders, and regions. Comprehensive prevention and control strategies should be formulated according to local conditions for different populations to further reduce the disease burden.
- 14 March 2026
- Vol. 47 (3) , 241-246
Open Access[Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].
Objective: This study aimed to analyze the disease burden and trends of Burkitt lymphoma (BL) in China between 1990 and 2021. Methods: Based on the 2021 Global Burden of Disease Study data, stratified by age, sex, and region, the disease burden was analyzed by BL incidence, mortality, and disability-adjusted life year (DALY). Regression analysis was conducted with joinpoint software to calculate the average annual percentage change (AAPC) of age-standardized rates to analyze the changing trends and compare them with global data. Results: In 2021, a total of 1,322 new BL cases were reported in China, with an age-standardized incidence rate of 0.08/100,000. Of these patients, 241 died, with an age-standardized mortality rate of 0.01/100,000. DALY was 9,516 person-years, with an age-standardized DALY rate of 0.68/100,000. The disease burden of BL demonstrated significant differences across various age and sex groups. The highest BL disease burden was observed in the age group over 80 years old, with an incidence of 0.60/100,000, mortality of 0.11/100,000, and DALY rates of 1.59/100,000. BL disease burden was higher in males than in females, with age-standardized incidence rates of 0.11/100,000 and 0.05/100,000, age-standardized mortality rates of 0.02/100,000 and 0.01/100,000, and age-standardized DALY rates of 0.92/100,000 and 0.43/100,000, respectively. Significant regional differences were observed in BL disease burden. The highest-ranked age-standardized DALY rates were reported in Shanghai [1.78 (95% CI: 0.16-3.63) /100,000], Tibet Autonomous Region [1.15 (95% CI: 0.41-2.23) /100,000] and Qinghai Province[1.06 (95% CI: 0.49-1.87) /100,000], whereas the lowest-ranked were observed in Macao Special Administrative Region [0.32 (95% CI: 0.07-0.57) /100,000], Chongqing [0.36 (95% CI: 0.14-0.72) /100,000] and Ningxia Hui Autonomous Region [0.48 (95% CI: 0.25-0.92) /100,000]. From 1990 to 2021, the age-standardized incidence rate of BL increased by 187.12%, whereas the age-standardized mortality rate and age-standardized DALY rate decreased by 37.72% and 52.70%, respectively. The AAPCs were 3.49%, -1.46%, and -2.40%, respectively. Conclusions: The disease burden of BL in China has been alleviated to a certain extent; however, significant differences were observed among different ages, genders, and regions. Comprehensive prevention and control strategies should be formulated according to local conditions for different populations to further reduce the disease burden.
- Open Access
- 20 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 39
Global burden of non-Hodgkin lymphoma in the elderly: a population-based study using GBD 2021
Elderly people are facing an increasing burden of non-Hodgkin lymphoma. However, accurate information on the NHL burden among elderly people remains limited. On the basis of the Global Burden of Diseases 2021, we described the global burden of non-Hodgkin lymphoma in people aged ≥ 65 years and estimated the effects of age, period, and birth cohort on disease burden. The estimated number of prevalent cases among people aged ≥ 65 years was 1,147,321 worldwide in 2021. The age-standardized prevalence rate was 148.21 per 100,000 population. There were 306,296 new cases and 158,813 deaths. The age-standardized rates of incidence and mortality were 59.20 and 21.46 per 100,000 population, respectively. The disease burden was greater in men than in women, and it varied across regions. High-sociodemographic index countries recorded the highest age-standardized incidence and mortality rates, while low-sociodemographic index countries exhibited relatively low incidence rate but high mortality rate. From 1990 to 2021, the incidence and prevalence tended to increase, whereas mortality and disability-adjusted life years tended to decrease. Age effects tended to increase overall mortality risk with increasing age. Period effects showed improvements in mortality after 2004, and cohort effects revealed progressively lower mortality risks in successive birth years after 1922. It is estimated that the age-standardized incidence rate will be relatively stable, whereas the age-standardized mortality rate is expected to decline rapidly by 2035. A focus on elderly men and the implementation of region-specific improvements in clinical diagnosis and treatment are needed.
- 20 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 39
Open AccessGlobal burden of non-Hodgkin lymphoma in the elderly: a population-based study using GBD 2021
Elderly people are facing an increasing burden of non-Hodgkin lymphoma. However, accurate information on the NHL burden among elderly people remains limited. On the basis of the Global Burden of Diseases 2021, we described the global burden of non-Hodgkin lymphoma in people aged ≥ 65 years and estimated the effects of age, period, and birth cohort on disease burden. The estimated number of prevalent cases among people aged ≥ 65 years was 1,147,321 worldwide in 2021. The age-standardized prevalence rate was 148.21 per 100,000 population. There were 306,296 new cases and 158,813 deaths. The age-standardized rates of incidence and mortality were 59.20 and 21.46 per 100,000 population, respectively. The disease burden was greater in men than in women, and it varied across regions. High-sociodemographic index countries recorded the highest age-standardized incidence and mortality rates, while low-sociodemographic index countries exhibited relatively low incidence rate but high mortality rate. From 1990 to 2021, the incidence and prevalence tended to increase, whereas mortality and disability-adjusted life years tended to decrease. Age effects tended to increase overall mortality risk with increasing age. Period effects showed improvements in mortality after 2004, and cohort effects revealed progressively lower mortality risks in successive birth years after 1922. It is estimated that the age-standardized incidence rate will be relatively stable, whereas the age-standardized mortality rate is expected to decline rapidly by 2035. A focus on elderly men and the implementation of region-specific improvements in clinical diagnosis and treatment are needed.
- Open Access
- 21 November 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1629229
Global burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021
Background: Hodgkin Lymphoma is a rare lymphatic system malignancy which has a negative impact on the health of children and adolescents. While high-income regions have seen a decline in mortality rates due to early diagnosis and advances in treatment strategies (e.g., chemotherapy, radiotherapy, and targeted therapy), low- and middle-income countries continue to face high mortality rates due to limited medical resources and delayed treatment. Methods: Employing data from the Global Burden of Disease (GBD) 2021 study, this analysis assessed the burden of Hodgkin lymphoma among children and adolescents from 1990 to 2021. Metrics including incidence, mortality, and disability-adjusted life years (DALYs) were evaluated across Socio-demographic Index (SDI) quintiles. Age-Period-Cohort (APC) and Nordpred models were used to analyze long-term trends and project future disease burden. Additionally, joinpoint regression analysis identified significant temporal shifts in trends throughout the study period. Results: The estimated DALY number was 265,016, and the ASDR among children and adolescents was 9.816 per 100,000 person in 2021. There were 8,700 new HL cases and 3,385 deaths, and the ASIR and ASMR were 0.320 and 0.125 per 100,000 population, respectively. The estimated number of prevalent HL cases was 50,128 worldwide with the ASPR of 2.001 per 100,000 population. Globally, the Hodgkin lymphoma burden was consistently higher in male children and adolescents than in females across all metrics. Results reveal a global decline in age-standardized incidence rates of HL among children and adolescents, with significant regional variations. Low- and middle-income regions experienced an increase in HL burden, while high-income regions showed a decline trend. The case number of HL in the children and adolescents increased from 8,283 in 1990 to 8,700 in 2021, while ASIR declined by 9.52%. The APC model projected a continued decline in HL incidence and mortality globally by 2040. However, health inequalities persist, with low-income countries bearing a disproportionately high burden of HL. Conclusions: The burden of HL among children and adolescents is increasing, with a significant difference by sex, age and regions, which highlight the urgent need for equitable diagnostic and therapeutic access in low-resource settings to meet the 2030 SDG targets on child health.
- 21 November 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1629229
Open AccessGlobal burden of Hodgkin lymphoma among children and adolescents: a population-based study using GBD 2021
Background: Hodgkin Lymphoma is a rare lymphatic system malignancy which has a negative impact on the health of children and adolescents. While high-income regions have seen a decline in mortality rates due to early diagnosis and advances in treatment strategies (e.g., chemotherapy, radiotherapy, and targeted therapy), low- and middle-income countries continue to face high mortality rates due to limited medical resources and delayed treatment. Methods: Employing data from the Global Burden of Disease (GBD) 2021 study, this analysis assessed the burden of Hodgkin lymphoma among children and adolescents from 1990 to 2021. Metrics including incidence, mortality, and disability-adjusted life years (DALYs) were evaluated across Socio-demographic Index (SDI) quintiles. Age-Period-Cohort (APC) and Nordpred models were used to analyze long-term trends and project future disease burden. Additionally, joinpoint regression analysis identified significant temporal shifts in trends throughout the study period. Results: The estimated DALY number was 265,016, and the ASDR among children and adolescents was 9.816 per 100,000 person in 2021. There were 8,700 new HL cases and 3,385 deaths, and the ASIR and ASMR were 0.320 and 0.125 per 100,000 population, respectively. The estimated number of prevalent HL cases was 50,128 worldwide with the ASPR of 2.001 per 100,000 population. Globally, the Hodgkin lymphoma burden was consistently higher in male children and adolescents than in females across all metrics. Results reveal a global decline in age-standardized incidence rates of HL among children and adolescents, with significant regional variations. Low- and middle-income regions experienced an increase in HL burden, while high-income regions showed a decline trend. The case number of HL in the children and adolescents increased from 8,283 in 1990 to 8,700 in 2021, while ASIR declined by 9.52%. The APC model projected a continued decline in HL incidence and mortality globally by 2040. However, health inequalities persist, with low-income countries bearing a disproportionately high burden of HL. Conclusions: The burden of HL among children and adolescents is increasing, with a significant difference by sex, age and regions, which highlight the urgent need for equitable diagnostic and therapeutic access in low-resource settings to meet the 2030 SDG targets on child health.
- Open Access
Genetic Subtype‐Based International Prognostic Index Prognostic Model in Diffuse Large B‐Cell Lymphoma
Molecular subtyping in diffuse large B‐cell lymphoma (DLBCL) leads to facilitating drug selection. However, an integrated prognostic model based on molecular subtyping and clinical features has not been well established. Here, we retrospectively performed whole genome sequencing, whole exome sequencing, and fluorescence in situ hybridization in newly diagnosed DLBCLs, established a simplified LymphType algorithm for classification evaluation, and proposed a new integrated prognostic stratification system, combined molecular subtypes and International Prognostic Index (IPI) scoring system in our in‐house sequencing cohort (N = 100), and validated in three public cohorts (N = 1480). Compared with IPI scoring system and classification algorithm model alone, the discrimination ability of prognostic model based on the new integrated model showed best discrimination of overall survival with concordance index value (0.773 vs. 0.724 vs. 0.648). We subsequently established a four‐category risk model defined for the integrated prognostic model as follows: low, low‐intermediate, high‐intermediate, and high risk, demonstrating stronger prognostic separation across all end points (all p < 0.001) in our in‐house cohort and three validation cohorts. Collectively, the new feasible integrated prognostic stratification system contributes to accurate prognosis assessment in clinical routine and provides a new basis for the follow‐up treatment.
Open AccessGenetic Subtype‐Based International Prognostic Index Prognostic Model in Diffuse Large B‐Cell Lymphoma
Molecular subtyping in diffuse large B‐cell lymphoma (DLBCL) leads to facilitating drug selection. However, an integrated prognostic model based on molecular subtyping and clinical features has not been well established. Here, we retrospectively performed whole genome sequencing, whole exome sequencing, and fluorescence in situ hybridization in newly diagnosed DLBCLs, established a simplified LymphType algorithm for classification evaluation, and proposed a new integrated prognostic stratification system, combined molecular subtypes and International Prognostic Index (IPI) scoring system in our in‐house sequencing cohort (N = 100), and validated in three public cohorts (N = 1480). Compared with IPI scoring system and classification algorithm model alone, the discrimination ability of prognostic model based on the new integrated model showed best discrimination of overall survival with concordance index value (0.773 vs. 0.724 vs. 0.648). We subsequently established a four‐category risk model defined for the integrated prognostic model as follows: low, low‐intermediate, high‐intermediate, and high risk, demonstrating stronger prognostic separation across all end points (all p < 0.001) in our in‐house cohort and three validation cohorts. Collectively, the new feasible integrated prognostic stratification system contributes to accurate prognosis assessment in clinical routine and provides a new basis for the follow‐up treatment.
- Open Access
- 19 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 23
Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation
Background: Patients with lymphoma and chronic hepatitis B virus infection need to be treated with both chemotherapy and nucleotide analogue (NA) therapy. However, dynamic changes in HBV DNA loads with increasing chemotherapy cycles are lacking. It is unknown whether HBV replication markers, namely, the quantitative hepatitis B core antibody (qAnti-HBc), HBV RNA, and the hepatitis B virus core-related antigen (HBcrAg), are also markers for predicting HBV reactivation (HBVr). Methods: From 29 June 2010 to 6 December 2021, the data of patients with single-site diffuse large B-cell lymphoma and HBV infection (HBsAg+ and HBsAg−/anti-HBc+) were collected from a hospital medical record system, retrospectively. Serum HBV DNA loads (using real-time fluorescent quantitative PCR tests), qAnti-HBc levels (using a newly developed chemiluminescent particle immunoassay), HBV RNA levels (using the simultaneous amplification testing method based on real-time fluorescence detection), and HBcrAg levels (using a Lumipulse G HBcrAg assay) were tested, and factors related to HBVr were analyzed. Results: Under NAs, the HBV DNA loads of 69 HBsAg+ lymphoma patients declined from 3.15 (2.13–4.73) lg IU/mL to 1.00 (1.00–1.75) lg IU/mL, and further declined to 1.00 (1.00–1.04) lg IU/mL at the end of a 24-month follow-up. The qAnti-HBc levels decreased gradually during chemotherapy in HBsAg+ lymphoma patients (F = 7.090, p = 0.009). The HBV RNA and HBcrAg levels remained stable. A multivariate analysis revealed that higher qAnti-HBc levels (1.97 ± 1.20 vs. 1.12 ± 0.84 lg IU/mL, OR = 6.369, [95% CI: 1.523–26.641], p = 0.011) and higher HBV RNA levels (1.00 ± 1.13 vs. 0.37 ± 0.80 lg copies/mL, OR = 3.299, [95% CI: 1.229–8.854], p = 0.018) were related to HBVr in HBsAg−/anti-HBc+ lymphoma patients. Conclusions: HBV DNA loads declined under NAs during chemotherapy in lymphoma patients. In HBsAg−/anti-HBc+ lymphoma patients, a higher level of baseline serum qAnti-HBc and HBV RNA levels can predict the likelihood of HBVr during chemotherapy.
- 19 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 23
Open AccessSteady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation
Background: Patients with lymphoma and chronic hepatitis B virus infection need to be treated with both chemotherapy and nucleotide analogue (NA) therapy. However, dynamic changes in HBV DNA loads with increasing chemotherapy cycles are lacking. It is unknown whether HBV replication markers, namely, the quantitative hepatitis B core antibody (qAnti-HBc), HBV RNA, and the hepatitis B virus core-related antigen (HBcrAg), are also markers for predicting HBV reactivation (HBVr). Methods: From 29 June 2010 to 6 December 2021, the data of patients with single-site diffuse large B-cell lymphoma and HBV infection (HBsAg+ and HBsAg−/anti-HBc+) were collected from a hospital medical record system, retrospectively. Serum HBV DNA loads (using real-time fluorescent quantitative PCR tests), qAnti-HBc levels (using a newly developed chemiluminescent particle immunoassay), HBV RNA levels (using the simultaneous amplification testing method based on real-time fluorescence detection), and HBcrAg levels (using a Lumipulse G HBcrAg assay) were tested, and factors related to HBVr were analyzed. Results: Under NAs, the HBV DNA loads of 69 HBsAg+ lymphoma patients declined from 3.15 (2.13–4.73) lg IU/mL to 1.00 (1.00–1.75) lg IU/mL, and further declined to 1.00 (1.00–1.04) lg IU/mL at the end of a 24-month follow-up. The qAnti-HBc levels decreased gradually during chemotherapy in HBsAg+ lymphoma patients (F = 7.090, p = 0.009). The HBV RNA and HBcrAg levels remained stable. A multivariate analysis revealed that higher qAnti-HBc levels (1.97 ± 1.20 vs. 1.12 ± 0.84 lg IU/mL, OR = 6.369, [95% CI: 1.523–26.641], p = 0.011) and higher HBV RNA levels (1.00 ± 1.13 vs. 0.37 ± 0.80 lg copies/mL, OR = 3.299, [95% CI: 1.229–8.854], p = 0.018) were related to HBVr in HBsAg−/anti-HBc+ lymphoma patients. Conclusions: HBV DNA loads declined under NAs during chemotherapy in lymphoma patients. In HBsAg−/anti-HBc+ lymphoma patients, a higher level of baseline serum qAnti-HBc and HBV RNA levels can predict the likelihood of HBVr during chemotherapy.
- Open Access
- 12 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (11) , 3185-3193
Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study
The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (p < 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%, p = 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%, p = 0.004; 3-year OS: 84.0% vs 74.1%, p = 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%, p = 0.042; 3-year OS: 84.8% vs 70.5%, p = 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.
- 12 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (11) , 3185-3193
Open AccessAutologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study
The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (p < 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%, p = 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%, p = 0.004; 3-year OS: 84.0% vs 74.1%, p = 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%, p = 0.042; 3-year OS: 84.8% vs 70.5%, p = 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.